Biomarkers have been a game-changer in helping oncologists and their medical teams select appropriate treatments, and a new guideline can provide detailed information about whether systemic therapy will benefit patients with metastatic breast cancer.
Biomarkers have been a game-changer in helping oncologists and their medical teams select appropriate treatments, and a new guideline can provide detailed information about whether systemic therapy will benefit patients with metastatic breast cancer.
Released in July 2015, the American Society of Clinical Oncology (ASCO) provided recommendations on the appropriate use of breast tumor biomarker assay results to guide decisions on systemic therapy for metastatic breast cancer.1
ASCO convened a panel of experts to develop clinical practice guideline recommendations based on a systematic review of relevant medical literature. The panel developed its recommendations based on evidence found on MEDLINE and the Cochrane Library (from January 2006 through September 2014, to overlap with the search end date for the 2007 guideline update on tumor markers in breast cancer) as well as the clinical experience of panel members.
The guideline “provides evidence-based guidance on ordering biomarker tests for this patient population,” Catherine Van Poznak, MD, of the University of Michigan Health System and co-chair of the metastatic breast cancer guideline told OncoTherapy Network. “The document outlines the use of biopsy materials from metastatic foci, and provides direction on the use of results from assays of predictive and/or prognostic breast tumor biomarkers. The guideline addresses which biomarkers have sufficient evidence to be used to guide decisions on systemic therapy for women with metastatic breast cancer.”
Key recommendations:1
In the era of evidence-based medicine, it is important to note that making a change midstream may not necessarily benefit the patient; this depends on the status of the patient, the goals of the patient and the medical team, and the current available data on the information at hand. These are not always straightforward clinical decisions.